Company

Bank

Analyst

Coverage

Opinion

Wk chg

1/31 cls

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)

Wells Fargo

Brian Abrahams

Downgrade

Market perform (from outperform)

-12%

$10.20

Abrahams downgraded but maintained his target of $9-$10 on the belief that BioCryst shares are now fairly valued. He continues to believe BCX4161 has a "reasonable probability" of meeting the primary endpoint in an ongoing Phase IIa trial to treat hereditary angioedema (HAE). BioCryst expects to report data from the trial this half. BCX4161 is a selective inhibitor of plasma kallikrein that subsequently suppresses bradykinin production.